Variables | R-TME (n = 38) | L-TME (n = 39) | P value |
---|---|---|---|
Age (years) | 47.75 ± 9.62 | 46.01 ± 9.37 | 0.424 |
BMI (kg/m2) | 21.34 ± 2.67 | 22.03 ± 2.51 | 0.246 |
ASA score n(%) | Â | Â | 0.301 |
 I | 22(57.9%) | 27(69.2%) |  |
 II | 16(42.1%) | 12(30.8%) |  |
Tumor location (cm) | 6.33 ± 2.21 | 5.82 ± 2.43 | 0.339 |
Neoadjuvant therapy n (%) | 9(23.7%) | 11(28.2%) | 0.651 |
Operation method n (%) | Â | Â | 0.591 |
 LAR | 32(84.2%) | 31(79.5%) |  |
 APR | 6(15.8%) | 8(20.5%) |  |
 Stoma n (%) | 8(21.1%) | 7(17.9%) | 0.731 |
Tumor differentiation n (%) | Â | Â | 0.826 |
 Well | 5(13.2%) | 6(15.4%) |  |
 Moderate | 25(65.8%) | 23(59.0%) |  |
 Poor | 8(21.0%) | 10(25.6%) |  |
Tumor stage n (%) | Â | Â | 0.367 |
 T1 | 3(5.3%) | 3(7.7%) |  |
 T2 | 10(26.3%) | 7(17.9%) |  |
 T3 | 22(57.9%) | 24(61.5%) |  |
 T4 | 3(7.9%) | 5(12.8%) |  |
Nodal stage n (%) | Â | Â | 0.761 |
 N0 | 28(73.7%) | 30(76.9%) |  |
 N1 | 7(18.4%) | 6(15.4%) |  |
 N2 | 3(7.9%) | 3(7.7%) |  |
 Adjuvant therapy n (%) | 13(34.2%) | 15(38.5%) | 0.114 |